Close menu
Brain & Behavior
Grants & Prizes
Home
Research
Illness
Addiction
Anxiety Disorders
Attention-Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Bipolar Disorder
Borderline Personality Disorder (BPD)
Depression
Eating Disorders
Mental Illness (General)
Obsessive-Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Schizophrenia
Suicide Prevention
Other Brain-Related Illnesses
Category
Basic Research
New Technologies
Early Intervention/ Diagnostic Tools
Next Generation Therapies
Blog
Get Involved
Give
Donate Today
Make a Memorial/Tribute Gift
Create an Event/Memorial Page
Find an Event/Memorial Page
Make a Stock/Securities Gift/IRA Charitable Rollover Gift
Donate Cryptocurrency
Get Involved
Other Giving Opportunities
$1 Million Challenge Match
Planned Giving
Research Partners
Donor Advised Funds
Workplace Giving
Team Up for Research!
Sponsorship Opportunities
Watch
Healthy Minds TV
Meet the Scientist Webinars
Videos
Connect
Ask the Expert
Join Us
Home
Grants
Grant FAQs
BBRF Young Investigator Grants
BBRF Independent Investigator Grants
BBRF Distinguished Investigator Grants
Prizes & Awards
Klerman & Freedman Prizes
Outstanding Achievement Prizes
Lieber Prize for Schizophrenia Research
Maltz Prize for Schizophrenia Research
Colvin Prize for Mood Disorders Research
Ruane Prize for Child and Adolescent Psychiatric Research
Goldman-Rakic Prize for Cognitive Neuroscience Research
The Pardes Humanitarian Prize
Productive Lives Awards
Blog
About Us
Who We Are
Our Impact
FAQs
Media Center
News
Press Releases
Opinion Pieces
In the News
Multimedia Library
Media Kit
Events & Webinars
Team Up for Research! Events
Healthy Minds TV
Contact
Email Signup
Open Menu

Menu

Can you envision ways in which the optogenetics technology that you invented might eventually improve the design or use of psychiatric medications?

Go Back to the Questions

Q. Can you envision ways in which the optogenetics technology that you invented might eventually improve the design or use of psychiatric medications?

Karl Deisseroth, M.D., Ph.D.
Answer By: Karl Deisseroth, M.D., Ph.D.

D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences

Howard Hughes Medical Institute Investigator

Stanford University
The major challenge we face in psychiatry is understanding. Psychiatric disease represents the leading cause of disability worldwide, but major pharmaceutical companies are withdrawing from developing new treatments, and many are shutting down psychiatry programs, a situation with major medical, social and economic implications. Reasons cited include the lack of neural circuit-level understanding of symptom states, which impairs identification of new treatments and development of predictive animal models. Part of the solution to this challenge may include technologies such as optogenetics, which has primary value as a research tool well-suited to probing circuit-level causality in complex behaviors. Identifying which patterns of circuit activity are actually causally involved in eliciting normal or pathological behaviors may provide a new kind of target, around which investigators can screen and build therapies (whether pharmacological, surgical, or electromagnetic).
Tags:
Depression
Ask an Expert

Related Articles

Study Indicates How rTMS Treatments Alter Neural Connectivity Brain-Wide in Treatment-Resistant Depressed Patients, a Clue to Predict Who Will Benefit

READ

Posted: Thursday, March 16, 2023

Study Indicates How rTMS Treatments Alter Neural Connectivity Brain-Wide in Treatment-Resistant Depressed Patients, a Clue to Predict Who Will Benefit

Read more
Large Machine-Learning Study Searches for Diagnostic Biomarkers in Major Depressive Disorder

READ

Posted: Thursday, March 2, 2023

Large Machine-Learning Study Searches for Diagnostic Biomarkers in Major Depressive Disorder

Read more
Talk Therapy + Brain Stimulation Reduced Suicidal Ideation in Patients with Borderline Personality Disorder and Treatment-Resistant Depression, Pilot Trial Shows

READ

Posted: Thursday, February 9, 2023

Talk Therapy + Brain Stimulation Reduced Suicidal Ideation in Patients with Borderline Personality Disorder and Treatment-Resistant Depression, Pilot Trial Shows

Read more
Brain Network Analysis Reveals a Depression – Multiple Sclerosis Connection

READ

Posted: Thursday, February 2, 2023

Brain Network Analysis Reveals a Depression – Multiple Sclerosis Connection

Read more